Research evidence / Overview of Studies for Biotrex
The research evidence for Biotrex (Levamisole) was studied for two distinct areas: its primary application against parasitic infections and its exploration in complex conditions involving systemic changes. This overview describes the types of research conducted, the outcomes measured, and the areas where data are limited.
Evidence for Anthelmintic Use (Parasitic Infections)
This section will summarize the highly established body of evidence, including Randomized Controlled Trials (RCTs) and comparative efficacy studies, that regulators rely on to assess the reported measurements of parasite clearance in susceptible nematode infections.
What Research Has Explored
Research has primarily focused on its use in adults and children with confirmed infections caused by certain parasitic worms. The study types include Randomized Controlled Trials (RCTs) and comparative efficacy studies, alongside large observational studies. The primary outcomes related to physiological strain that was observed in the studies included the parasite clearance rate (the proportion of patients achieving clearance) and the reduction in egg counts found in stool samples.
What the Studies Reported
Findings describe patterns observed in the studies where follow-up testing showed clearance measurements in a large portion of the observed populations shortly after the study period. Research highlights changes measured during the study period, where studies monitored patterns of reduction in the number of eggs produced by the parasites. This evidence is generally recognized by global health authorities as relevant in evidence describing how symptoms are measured in these specific parasitic infections.
Evidence for Immunomodulatory Use (Adjuvant Therapy and Immune Conditions)
This area will focus on the research landscape, primarily consisting of long-term RCTs conducted in specific oncology settings (e.g., adjuvant colon cancer) and the smaller prospective trials that investigated its potential role in various conditions involving systemic changes.
What Research Has Explored
Research examined the potential role of Biotrex as an adjuvant, or supportive, therapy, particularly in combination with chemotherapy for patients who had undergone surgery for specific stages of colon cancer. This investigation involved large-scale, long-term RCTs where measures of disease progression were monitored for many years. Studies explored outcomes related to systemic changes, also monitoring shifts in immune biomarkers (such as T-cell activity) in the observed populations. Research also explored its use in conditions characterized by fluctuating or episodic manifestations, such as certain skin diseases or kidney conditions in children.
What the Studies Reported
In the long-term oncology trials, data was observed in some studies related to long-term patient monitoring during the study period, particularly when the medicine was studied in combination with other treatments. Follow-up data from these studies also provided context on long-term tracking of patient outcomes. However, findings were mixed across different types of cancer (such as melanoma) and across different immune-mediated conditions, where evidence is limited to smaller prospective trials. Research describes that the observed outcomes may have been associated with specific variables, including the patient's immune status and the specific regimen used in the study.
Long-Term Studies and Durability of Outcomes
This part will summarize what is known about the extended tracking of patient outcomes, including the durability of the anthelmintic effect and the long-term monitoring reported in the clinical trials conducted for its use in conditions involving systemic changes.
Long-term effects are not fully established for all areas of its use, and there is limited information for long-term outcomes. For parasitic infections, the follow-up durations were limited to confirm parasite clearance. In the studies exploring systemic changes, research examined outcomes related to physical discomfort over extended periods, with some trials tracking patients for a median of ten years. These studies contribute to the broader evidence landscape related to long-term monitoring.
Inconsistent Findings and Evidence Gaps
Evidence quality varies across studies, particularly in the area of systemic changes where findings were mixed and results were not consistently observed across different conditions. The research highlights what is known—and what is still uncertain. Comparative evidence is lacking in some areas, and the findings indicate that patterns of observed outcomes may have been associated with the patient's immune status, dose, and timing. Furthermore, some studies needed to be modified, including dose adjustments due to safety concerns, which created limitations in the analysis of the planned regimen. Certainty remains low for many of its researched applications outside of parasitic infection control.
